| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 14,344 | 12,702 | 3,439 | -1,781 |
| Cost of product revenue | 754 | 340 | 423 | 351 |
| Cost of collaboration revenue | 355 | 154 | 14 | 84 |
| Selling, general and administrative | 9,403 | 8,852 | 8,848 | 16,083 |
| Research and development | 2,205 | 1,846 | 2,284 | 2,405 |
| Total operating expenses | 12,717 | 11,192 | 11,569 | 18,923 |
| Income (loss) from operations | 1,627 | 1,510 | -8,130 | -20,704 |
| Interest income | 159 | 228 | 337 | 221 |
| Interest expense | 2,094 | 2,131 | 2,203 | 2,376 |
| Change in fair value of derivative liability | 34 | 598 | 254 | - |
| Other expense | 0 | -1 | - | -1 |
| Total other expense, net | -1,901 | -1,306 | -1,612 | -2,156 |
| Net loss | -274 | 204 | -9,742 | -22,860 |
| Net loss per share, basic (in dollars per share) | -0.03 | 0.02 | -0.1 | -0.49 |
| Net loss per share, diluted (in dollars shares) | -0.03 | 0.02 | -0.1 | -0.49 |
| Weighted-average common shares outstanding, basic (in shares) | 9,490,083 | 9,488,055 | 94,837,343 | 46,805,427 |
| Weighted-average common shares outstanding, diluted (in shares) | 9,490,083 | 9,490,600 | 94,837,343 | 46,805,427 |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)